Isis Pharmaceuticals, Inc. (ISIS) - Financial and Strategic SWOT Analysis Review

Document Sample
Isis Pharmaceuticals, Inc. (ISIS) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					                 Isis Pharmaceuticals, Inc. (ISIS) - Financial and Strategic SWOT
                                         Analysis Review
        Reference Code: GDPH5161FSA                                                                                           Publication Date: APR 2013

          2855 Gazelle Court                                 Phone              +1 760 9319200                  Revenue          102.1 (million USD)
          Carlsbad, CA                                       Fax                +1 302 6555049                  Net Profit       -65.48 (million USD)
          92010                                              Website            www.isispharm.com               Employees        288
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           ISIS [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Isis Pharmaceuticals, Inc. (Isis) is a pharmaceutical company specialized in antisense technology. The company carries out the
       discovery and development of new class antisense drugs that address significant unmet medical needs. Antisense technology is
       a direct route from genomics to drugs. The product pipeline of the company focuses on various therapeutic areas, namely,
       cardiovascular, cancer, metabolic, neurodegenerative, inflammatory and other diseases. Isis lead product KYNAMRO is in Phase
       III of clinical trial and being developed under collaboration with Genzyme for the reduction of low-density lipoprotein cholesterol.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Isis Pharmaceuticals, Inc., SWOT Analysis
         Stanley T. Crooke, M.D., Chairman                                            Strengths                              Weaknesses
         Ph.D.
                                                                                      Patented Antisense Technology Limited Manufacturing Facilities
         B. Lynne Parshall                   Chief Operating Officer
         Joseph Klein                        Director                                 Intellectual Property                  Weak Financial Performance
         Spencer      R.     Berthelsen, Director
         M.D.                                                                         Opportunities                          Threats
         Frederick T. Muto                   Director
                                                                                      Demographic Trends                     Increased Pricing Control
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData
                                                                                      Product Pipeline                       Uncertain R&D Outcomes
       Share Data
         Isis Pharmaceuticals, Inc.                                                  Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        Share Price (USD) as on 28-Mar-                                16.94
        2013
        EPS (USD)                                                       -0.65
        Market Cap (million USD)                                       1,725
        Enterprise Value (million USD)                                 1,827
        Shares Outstanding (million)                                     102
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 28, 2013         Isis Reports Revenue Of $102m In 2012
                                                                                      Feb 04, 2013         Rosalind Franklin University Scientists Prevent
                                                                                                           Development Of Deafness In Animals
                                                                                                           Engineered To Have Usher Syndrome
                                                                                      Nov 06, 2012         Isis Reports Revenue Of $11.6m In Q3 2012
                                                                                      Oct 24, 2012         Isis Pharma To Receive $1.1m Milestone
                                                                                                           Payment From Alnylam Pharma
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData

       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Isis Pharmaceuticals, Inc. (ISIS) - Financial and Strategic SWOT                                                                Reference Code: GDPH5161FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Isis Pharmaceuticals, Inc. - Key Facts ................................................................................................................................................ 5
       Isis Pharmaceuticals, Inc. - Key Employees ....................................................................................................................................... 6
       Isis Pharmaceuticals, Inc. - Key Employee Biographies ..................................................................................................................... 7
       Isis Pharmaceuticals, Inc. - Major Products and Services .................................................................................................................. 8
       Isis Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data.................................................................................................. 9
          Isis Pharmaceuticals, Inc., Pipeline Products by Therapy Area ...................................................................................................... 9
          Isis Pharmaceuticals, Inc., Pipeline Products by Development Phase.......................................................................................... 10
       Isis Pharmaceuticals, Inc. - History .................................................................................................................................................. 13
       Isis Pharmaceuticals, Inc. - Company Statement ............................................................................................................................. 17
       Isis Pharmaceuticals, Inc. - Locations And Subsidiaries................................................................................................................... 20
          Head Office ................................................................................................................................................................................... 20
          Other Locations & Subsidiaries ..................................................................................................................................................... 20
       Section 2 – Company Analysis ......................................................................................................................................................... 21
       Isis Pharmaceuticals, Inc. - Business Description ............................................................................................................................ 21
       Isis Pharmaceuticals, Inc. - Corporate Strategy ............................................................................................................................... 23
       Isis Pharmaceuticals, Inc. - SWOT Analysis..................................................................................................................................... 24
          SWOT Analysis - Overview........................................................................................................................................................... 24
          Isis Pharmaceuticals, Inc. - Strengths ........................................................................................................................................... 24
             Strength - Patented Antisense Technology ............................................................................................................................... 24
             Strength - Intellectual Property .................................................................................................................................................. 24
             Strength - Strategic Collaborations ........................................................................................................................................... 24
          Isis Pharmaceuticals, Inc. - Weaknesses...................................................................................................................................... 25
             Weakness - Limited Manufacturing Facilities ............................................................................................................................ 25
             Weakness - Weak Financial Performance ................................................................................................................................ 25
             Weakness - Legal Proceedings ................................................................................................................................................. 25
          Isis Pharmaceuticals, Inc. - Opportunities ..................................................................................................................................... 25
             Opportunity - Demographic Trends ........................................................................................................................................... 25
             Opportunity - Product Pipeline .................................................................................................................................................. 25
             Opportunity - ISIS-SMN: Orphan Drug Designation .................................................................................................................. 26
          Isis Pharmaceuticals, Inc. - Threats .............................................................................................................................................. 26
             Threat - Increased Pricing Control............................................................................................................................................. 26
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 27
             Threat - Stringent Government Regulations .............................................................................................................................. 27
       Isis Pharmaceuticals, Inc. - Key Competitors ................................................................................................................................... 28
       Section 3 – Company Financial Ratios ............................................................................................................................................. 29
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 29
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 29
       Performance Chart ........................................................................................................................................................................... 31
       Financial Performance...................................................................................................................................................................... 31
       Financial Ratios - Interim Ratios....................................................................................................................................................... 32
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 33


Isis Pharmaceuticals, Inc. (ISIS) - Financial and Strategic SWOT                                                                                                 Reference Code: GDPH5161FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 34
          Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ................................................... 34
          Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ................................................... 35
       Isis Pharmaceuticals, Inc., Recent Deals Summary ......................................................................................................................... 36
       Section 5 – Company’s Recent Developments ................................................................................................................................ 37
          Isis Pharmaceuticals, Inc., Recent Developments ........................................................................................................................ 37
             Feb 28, 2013: Isis Reports Revenue Of $102m In 2012 ........................................................................................................... 37
             Feb 04, 2013: Rosalind Franklin University Scientists Prevent Development Of Deafness In Animals Engineered To Have
             Usher Syndrome ....................................................................................................................................................................... 39
             Nov 06, 2012: Isis Reports Revenue Of $11.6m In Q3 2012 .................................................................................................... 40
             Oct 24, 2012: Isis Pharma To Receive $1.1m Milestone Payment From Alnylam Pharma ....................................................... 41
             Sep 25, 2012: Isis Pharma Discovers User Access With Varonis's DatAdvantage ................................................................... 42
             Sep 06, 2012: Isis Pharma Expands Use Of BioClinica Express EDC .............................................................................
				
DOCUMENT INFO
Description: Isis Pharmaceuticals, Inc. (Isis) is a pharmaceutical company specialized in antisense technology. The company carries out the discovery and development of new class antisense drugs that address significant unmet medical needs. Antisense technology is a direct route from genomics to drugs. The product pipeline of the company focuses on various therapeutic areas, namely, cardiovascular, cancer, metabolic, neurodegenerative, inflammatory and other diseases. Isis lead product KYNAMRO is in Phase III of clinical trial and being developed under collaboration with Genzyme for the reduction of low-density lipoprotein cholesterol.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.